Loading...
 

Volume 35, Issue 1, March 2024



Sign in to download the Issue in PDF format.

Back to the list
Mediterr J Rheumatol 2023;34(4):486-94
Article Links
Regulatory B Cells Evaluation in Systemic Lupus Erythematosus Patients with Subclinical Atherosclerosis and Secondary Antiphospholipid Syndrome
Marwa Mahmoud Abdelaziz1, Nihal Fathi1, Helal F. Hetta2, Ahmed Abdel-Galeel3, Mohamed Zidan4, Eman M. Shawky1, Rania M. Gamal1
Authors Information

1Rheumatology and Rehabilitation Department, Faculty of Medicine, Assiut University, Assiut, Egypt

2Medical Microbiology and Immunology Department, Faculty of Medicine, Assiut University, Assiut, Egypt

3Cardiovascular Medicine Department, Heart Hospital, Faculty of Medicine, Assiut University, Assiut, Egypt

4Diagnostic Radiology Department, Faculty of Medicine, Assiut University, Assiut, Egypt

 

MM Abdelaziz

Keywords: systemic lupus erythematosus, subclinical atherosclerosis, secondary antiphospholipid syndrome, B-lymphocytes, Breg cells
References
  1. He J, Ma J, Ren B, Liu A. Advances in systemic lupus erythematosus pathogenesis via mTOR signaling pathway. Semin Arthritis Rheum 2020;50(2):314-420. 
  2. Rafieian-Kopaei M, Setorki M, Doudi M, Baradaran A, Nasri H. Atherosclerosis: process, indicators, risk factors and new hopes. Int J Prev Med 2014;5:927-46.
  3. Blair PA, Norena LY, Flores-Borja F, Rawlings DJ, Isenberg DA, Ehrenstein MR, et al. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity 2010;32:129-40.
  4. Roman MJ, Shanker B-A, Davis A, Lockshin MD, Sammaritano L, Simantov R, et al.  Prevalence and Correlates of Accelerated Atherosclerosis in Systemic Lupus Erythematosus. N Engl J Med 2003; 349(25):2399-406.
  5. Lerang K, Gilboe IM, Steinar Thelle D, Gran JT. Mortality and years of potential life loss in systemic lupus erythematosus: a population-based cohort study. Lupus 2014;23(14):1546-52.
  6. Urowitz MB, Ibañez D, Gladman DD. Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors. J Rheumatol 2007;34:70-5.
  7. Lozovoy MAB, Simao ANC, Hohmann MSN, Simão T N C, Barbosa D S, Morimoto H K, et al. Inflammatory biomarkers and oxidative stress measurements in patients with systemic lupus erythematosus with or without metabolic syndrome. Lupus 2011;20:1356-64.
  8. Prechl JCB, Czirják L. The endothelial deprotection hypothesis for lupus pathogenesis: the dual role of C1q as a mediator of clearance and regulator of endothelial permeability. F1000Res 2015; 26:4:24.  
  9. Camejo G, Olofsson SO, Lopez F, Carlsson P, Bondjers G. Identification of Apo B-100 segments mediating the interaction of low density lipoproteins with arterial proteoglycans. Arteriosclerosis 1988;8(4):368-77.
  10. Tsiantoulas D, Diehl CJ, Witztum JL, Binder CJ. B cells and humoral immunity in atherosclerosis. Circ Res 2014;114:1743-56.
  11. Shao WH, Cohen PL. Disturbances of apoptotic cell clearance in systemic lupus erythematosus. Arthritis Res Ther 2011;13(1):202.
  12. Wilhelm AJ, Major AS. Accelerated atherosclerosis in SLE: mechanisms and prevention approaches. Int J Clin Rheumtol 2012;7(5):527-39.
  13. Wigren M, Nilsson J, Kaplan MJ. Pathogenic immunity in systemic lupus erythematosus and atherosclerosis: common mechanisms and possible targets for intervention. J Intern Med 2015;278:494-506.
  14. Miyagaki T. Regulatory b cells in human autoimmune diseases. Nihon Rinsho Meneki Gakkai Kaishi 2015;38:390-7.
  15. Strom AC, Cross AJ, Cole JE, Blair PA, Leib C, Goddard ME, et al. B regulatory cells are increased in hypercholesterolaemic mice and protect from lesion development via IL-10. Thromb Haemost 2015;114:835-47.
  16. Petri M, Orbai A-M, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of Systemic Lupus International Collaborating Clinics (SLICC) classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677-86.
  17. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002;29:288-91.
  18. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G. Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25(6):1105-87.
  19. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, M Viamonte Jr, Detrano R. Quantification of coronary-artery calcium using ultrafast computed-tomography. J Am Coll Cardiol 1990;15:827-32.
  20. McMahon M, Skaggs B. Pathogenesis and treatment of atherosclerosis in lupus. Rheum Dis Clin North Am 2014;40:475-95.
  21. Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S, et al. Premature coronary artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2407-15.
  22. Yiu KH, Wang S, Mok MY, Ooi GC, Khong PL, Mak KFH, et al. Pattern of arterial calcification in patients with systemic lupus erythematosus. J Rheumatol 2009;36:2212-7.
  23. Ward MM. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 1999;42(2):338-46.
  24. Sangiorgi G, Rumberger JA, Severson A, Edwards WD, Gregoire J, Fitzpatrick LA, et al. Arterial calcification and not lumen stenosis is highly correlated with atherosclerotic plaque burden in humans: a histologic study of 723 coronary artery segments using nondecalcifying methodology. J Am Coll Cardiol 1998;31(1):126-33.
  25. Kay SD, Poulsen MK, Diederichsen ACP, Voss A. Coronary, Carotid, and Lower-extremity Atherosclerosis and Their Interrelationship in Danish Patients with Systemic Lupus Erythematosus. J Rheumatol 2016;43(2):315-22.
  26. Tyrrell PN, Beyene J, Feldman BM, Mccrindle BW, Silverman ED, Bradley TJ. Rheumatic disease and carotid intima-media thickness: a systematic review and meta-analysis. Arterioscler Thromb Vasc Biol 2010;30(5):1014-26.
  27. Doria A, Shoenfeld Y, Wu R, Gambari PF, Puato M, Ghirardello A, et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2003; 62(11):1071-7.
  28. Gallelli B, Burdick L, Quaglini S, Banfi G, Novembrino C, Bamonti F, et al. Carotid plaques in patients with long-term lupus nephritis. Clin Exp Rheumatol 2010;28(3):386-92.
  29. Sazliyana S, Shahrir MSM, Kong NCT, Tan HJ, Hamidon BB, Azmi MT. Thickened carotid intima media thickness and carotid atherosclerosis among lupus nephritis patients: the role of traditional and lupus-specific factors. Int J Rheum Dis 2011;14(3):267-75.
  30. Oryoji K, Kiyohara C, Horiuchi T, Tsukamoto H, Niiro H, Shimoda T, et al.  Reduced carotid intima-media thickness in systemic lupus erythematosus patients treated with cyclosporine A. Mod Rheumatol 2014;24(1):86-92.
  31. Kisiel B, Kruszewski R, Juszkiewicz A, Bachta A, Krzysztof K, Duda K, et al.  Systemic lupus erythematosus: the influence of disease-related and classical risk factors on intima media thickness and prevalence of atherosclerotic plaques - a preliminary report.Beneficial effect of immunosuppressive treatment on carotid intima media thickness. Acta Cardiol 2015;70(2):169-75.
  32. Menon M, Blair PA, Isenberg DA, Mauri C. A regulatory feedback between plasmacytoid dendritic cells and regulatory B cells is aberrant in systemic lupus erythematosus. Immunity 2016;44(3):683-97.
  33. Jian EW, Zhao LL, Li YL. Expression and significance of CD19+CD5+ B cells and IL-10 in patients with systemic lupus erythematosus. China Journal of Modern Medicine 2016; 26(11):59-62.
  34. Gao N, Dresel J, Eckstein V, Gellert R, Störch H, Venigalla R, et al. Impaired suppressive capacity of activation-induced regulatory B cells in systemic lupus erythematosus. Arthritis Rheumatol 2014; 66(10):2849-61.
  35. Yang X, Yang JI, Chu Y, Xue YU, Xuan D, Zheng S, et al. T Follicular Helper Cells and Regulatory B Cells Dynamics in Systemic Lupus Erythematosus. PLoS One 2014; 9(2):e88441.
  36. Blair PA, Chavez-Rueda KA, Evans JG, Shlomchik MJ, Eddaoudi A, Isenberg DA, et al. Selective Targeting of B cells with Agonistic Anti- CD40 is an Efficacious Strategy for the Generation of Induced Regulatory T2-Like B Cells and for the Suppression of Lupus in MRL/lpr Mice. J Immunol 2009;182:3493-502.
  37. Liu Y, Duan WR, Liu Sa, Liu T, Chang YJ, Fan XM.  Correlation of CD19+CD24hiCD38hi B cells in coronary artery disease with severity of atherosclerosis. Chin Med J (Engl) 2020;133(10):1257-8.
  38. Sanz I, Lee FE-H.  B cells as therapeutic targets in SLE. Nat Rev Rheumatol 2010; 6(6):326-37.
  39. Manzi S, Selzer F, Sutton-Tyrrell K, Fitzgerald SG, Rairie JE, Tracy RP, et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 1999;42(1):51-60.
  40. Lewandowski LB, Kaplan MJ. Update on cardiovascular disease in lupus. Curr Opin Rheumatol 2016;28(5):468-76.
  41. Ammirati E, Bozzolo E, Contri R, Baragetti A, Palini A, Cianflone D, et al. Cardiometabolic and immune factors associated with increased common carotid artery intima-media thickness and cardiovascular disease in patients with systemic lupus erythematosus. Nutr Metab Cardiovasc Dis 2014;24(7):751-9.
  42. Ronda N, Favari E, Borghi MO, Ingegnoli F, Gerosa M, Chighizola C, et al. Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis 2014;73(3):609-15.
  43. McMahon M, Grossman J, Skaggs B, Fitzgerald J, Sahakian L, Ragavendra N, et al. Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheum 2009; 60(8):2428-37.
  44. Zhou X, Robertson A-KL, Rudling M, Parini P, Hansson GK. Lesion development and response to immunization reveal a complex role for CD4 in atherosclerosis. Circ Res 2005; 96(4):427-34.
  45. Padjas A, Płazak W, Celińska-Lowenhoff M, Mazurek A, Perricone C, Podolec P, et al. Myocardial ischaemia, coronary atherosclerosis and pulmonary pressure elevation in antiphospholipid syndrome patients. Adv Clin Exp Med 2016; 25(6): 1199-205.
  46. Sherer Y, Shoenfeld Y. Antiphospholipid antibodies: Are they proatherogenic or an epiphenomenona of atherosclerosis? Immunobiology 2003;207: 13-6.
  47. Majka DS,  Liu K,  Pope RM,  Karlson EW, Vu THT, Teodorescu M, et al. Antiphospholipid antibodies and sub-clinical atherosclerosis in the coronary artery risk development in young adults (CARDIA) cohort. Inflamm Res 2013;62(10):919-27.
  48. de Groot PG, de Laat B. Mechanisms of thrombosis in systemic lupus erythematosus and antiphospholipid syndrome. Best Pract Res Clin Rheumatol 2017;31(3):334-41.
  49. Di Minno MND, Emmi G, Ambrosino P, Scalera A, Tufano A , Cafaro G, et al. Impact of cardiovascular and immunologic variables on subclinical carotid atherosclerosis in subjects with anti-phospholipid antibodies. Data in Brief 2018;19:1799-803.